What We See for 2023: The Pharma Advertising Trends Taking Our Industry by Storm

Today’s healthcare marketers have access to more digital health data than ever. We think of that data as oil and programmatic advertising as its engine, working together to supercharge pharma advertising campaign results.

With more advancements in data and measurement, CTV’s continued explosive growth, the ever-evolving privacy landscape, and the looming death of the third-party cookie, that car is only going to keep accelerating. We’re calling it now: 2023 will be a pivotal year for pharmaceutical advertising.

But how? We posed that question to top pharma and ad-tech industry leaders from DeepIntent, our clients, and our partners.

Complete the form to receive a copy of What We See for 2023: The Pharma Advertising Trends Taking Our Industry by Storm and get a glimpse into the future.

Our Partners

Share this Post

Related Articles

As health marketing undergoes rapid disruption around privacy and identity, delivering personalized messaging at scale becomes a steeper challenge—and an even more important goal. It isn’t just about “selling” more products. It’s about finding new ways to reach people and improve health outcomes. At AdLab Health Marketing Summit, DeepIntent Founder and CEO Chris Paquette urged […]

Proven to drive audience quality (AQ) and script lift, DeepIntent Outcomes™ is the industry’s fastest measurement solution based on clinical data. Download our eBooklet for a look at how Outcomes helped some of the leading pharma brands achieve: 164% higher audience quality over the course of a campaign 27% higher script lift within the first […]

With the rapid rise of streaming in recent years, it’s a common misconception that older audiences are still spending the majority of their viewing time with linear TV — a belief that has kept most pharma advertising investments focused on traditional channels. As one of the most important demographics for pharma, we set out to […]

Never Miss New Insights

Sign up for the newsletter to ensure our latest whitepapers, research reports, and more are delivered to your inbox.